Cargando…

Potential treatments of COVID-19: Drug repurposing and therapeutic interventions

The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The infection is caused when Spike-protein (S-protein) present on the surface of SARS-CoV-2 interacts with human cell surface receptor, Angiotensin-converting enzyme 2 (ACE2). This bind...

Descripción completa

Detalles Bibliográficos
Autores principales: Raghav, Pawan Kumar, Mann, Zoya, Ahluwalia, Simran Kaur, Rajalingam, Raja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930377/
https://www.ncbi.nlm.nih.gov/pubmed/37059487
http://dx.doi.org/10.1016/j.jphs.2023.02.004
_version_ 1784889035917885440
author Raghav, Pawan Kumar
Mann, Zoya
Ahluwalia, Simran Kaur
Rajalingam, Raja
author_facet Raghav, Pawan Kumar
Mann, Zoya
Ahluwalia, Simran Kaur
Rajalingam, Raja
author_sort Raghav, Pawan Kumar
collection PubMed
description The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The infection is caused when Spike-protein (S-protein) present on the surface of SARS-CoV-2 interacts with human cell surface receptor, Angiotensin-converting enzyme 2 (ACE2). This binding facilitates SARS-CoV-2 genome entry into the human cells, which in turn causes infection. Since the beginning of the pandemic, many different therapies have been developed to combat COVID-19, including treatment and prevention. This review is focused on the currently adapted and certain other potential therapies for COVID-19 treatment, which include drug repurposing, vaccines and drug-free therapies. The efficacy of various treatment options is constantly being tested through clinical trials and in vivo studies before they are made medically available to the public.
format Online
Article
Text
id pubmed-9930377
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
record_format MEDLINE/PubMed
spelling pubmed-99303772023-02-15 Potential treatments of COVID-19: Drug repurposing and therapeutic interventions Raghav, Pawan Kumar Mann, Zoya Ahluwalia, Simran Kaur Rajalingam, Raja J Pharmacol Sci Full Paper The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The infection is caused when Spike-protein (S-protein) present on the surface of SARS-CoV-2 interacts with human cell surface receptor, Angiotensin-converting enzyme 2 (ACE2). This binding facilitates SARS-CoV-2 genome entry into the human cells, which in turn causes infection. Since the beginning of the pandemic, many different therapies have been developed to combat COVID-19, including treatment and prevention. This review is focused on the currently adapted and certain other potential therapies for COVID-19 treatment, which include drug repurposing, vaccines and drug-free therapies. The efficacy of various treatment options is constantly being tested through clinical trials and in vivo studies before they are made medically available to the public. The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. 2023-05 2023-02-15 /pmc/articles/PMC9930377/ /pubmed/37059487 http://dx.doi.org/10.1016/j.jphs.2023.02.004 Text en © 2023 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Full Paper
Raghav, Pawan Kumar
Mann, Zoya
Ahluwalia, Simran Kaur
Rajalingam, Raja
Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
title Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
title_full Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
title_fullStr Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
title_full_unstemmed Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
title_short Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
title_sort potential treatments of covid-19: drug repurposing and therapeutic interventions
topic Full Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930377/
https://www.ncbi.nlm.nih.gov/pubmed/37059487
http://dx.doi.org/10.1016/j.jphs.2023.02.004
work_keys_str_mv AT raghavpawankumar potentialtreatmentsofcovid19drugrepurposingandtherapeuticinterventions
AT mannzoya potentialtreatmentsofcovid19drugrepurposingandtherapeuticinterventions
AT ahluwaliasimrankaur potentialtreatmentsofcovid19drugrepurposingandtherapeuticinterventions
AT rajalingamraja potentialtreatmentsofcovid19drugrepurposingandtherapeuticinterventions